{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:44:44Z","timestamp":1785285884331,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11906-020-1021-0","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T11:02:35Z","timestamp":1582974155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls"],"prefix":"10.1007","volume":"22","author":[{"given":"Andrea M.","family":"Berrido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-3520","authenticated-orcid":false,"given":"James Brian","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"\u2022 Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet. 2003;362:759\u201366 This clinical trial report raised a concern about whether ARBs might cause an increase in cancer cases.","journal-title":"Lancet"},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMp1901657","volume":"380","author":"JB Byrd","year":"2019","unstructured":"\u2022 Byrd JB, Chertow GM, Bhalla V. Hypertension hot potato - anatomy of the angiotensin-receptor blocker recalls. N Engl J Med. 2019;380:1589\u201391 A detailed timeline plus clinical perspective on the angiotensin receptor blocker recalls.","journal-title":"N Engl J Med"},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2017.10.073","volume":"71","author":"P Muntner","year":"2018","unstructured":"Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, et al. Potential U.S. population impact of the 2017 ACC\/AHA high blood pressure guideline. J Am Coll Cardiol. 2018;71:109\u201318.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"1021_CR4","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1038\/sj.jhh.1001352","volume":"16","author":"R Hern\u00e1ndez-Hern\u00e1ndez","year":"2002","unstructured":"Hern\u00e1ndez-Hern\u00e1ndez R, Sosa-Canache B, Velasco M, Armas-Hern\u00e1ndez MJ, Armas-Padilla MC, Cammarata R. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens. 2002;16(Suppl 1):S93\u20139.","journal-title":"J Hum Hypertens"},{"key":"1021_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585\u201392.","journal-title":"N Engl J Med"},{"key":"1021_CR6","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e13\u2013115.","journal-title":"Hypertension"},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"169S","DOI":"10.1378\/chest.129.1_suppl.169S","volume":"129","author":"PV Dicpinigaitis","year":"2006","unstructured":"Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:169S\u201373S.","journal-title":"Chest"},{"key":"1021_CR8","doi-asserted-by":"crossref","unstructured":"Li ECK, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;CD009096.","DOI":"10.1002\/14651858.CD009096.pub2"},{"key":"1021_CR9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.18553\/jmcp.2010.16.9.671","volume":"16","author":"B Bian","year":"2010","unstructured":"Bian B, Kelton CML, Guo JJ, Wigle PR. ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm. 2010;16:671\u20139.","journal-title":"J Manag Care Pharm"},{"key":"1021_CR10","unstructured":"Center for Drug Evaluation and Research. Approval package for: application number ANDA 90-790. [cited 2019 Dec 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/anda\/2010\/090790Orig1s000.pdf"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858\u201371.","journal-title":"JAMA"},{"key":"1021_CR12","unstructured":"Kane SP, Phar, BCPS. Losartan potassium - drug usage statistics, ClinCalc DrugStats Database. ClinCalc. [cited 2019 Dec 18]. Available from: https:\/\/clincalc.com\/DrugStats\/Drugs\/LosartanPotassium"},{"key":"1021_CR13","unstructured":"Kane SP, Phar, BCPS. Valsartan - drug usage statistics, ClinCalc DrugStats Database. ClinCalc. [cited 2019 Dec 18]. Available from: https:\/\/clincalc.com\/DrugStats\/Drugs\/Valsartan"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/CS20100389","volume":"120","author":"LM Willis","year":"2011","unstructured":"\u2022 Willis LM, El-Remessy AB, Somanath PR, Deremer DL, Fagan SC. Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci. 2011;120:307\u201319 A detailed review of the effects of ARBs on angiogenesis, which in at least some contexts affects the ability of a tumor to grow.","journal-title":"Clin Sci"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","volume":"26","author":"CI Coleman","year":"2008","unstructured":"Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008;26:622\u20139.","journal-title":"J Hypertens"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"\u2022 Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:65\u201382 One of several meta-analyses of clinical trials intended to determine whether there is a risk of cancer conferred by ARB exposure.","journal-title":"Lancet Oncol"},{"key":"1021_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","volume":"29","author":"ARB Trialists Collaboration","year":"2011","unstructured":"ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623\u201335.","journal-title":"J Hypertens"},{"key":"1021_CR19","unstructured":"FDA drug safety communication: no increase in risk of cancer with certain blood pressure drugs--angiotensin receptor blockers (ARBs). U.S. Food and Drug Administration. 2011 [cited 2020 Jan 13]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-no-increase-risk-cancer-certain-blood-pressure-drugs-angiotensin."},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"e3600","DOI":"10.1097\/MD.0000000000003600","volume":"95","author":"Y-T Zhao","year":"2016","unstructured":"Zhao Y-T, Li P-Y, Zhang J-Q, Wang L, Yi Z. Angiotensin II receptor blockers and cancer risk: a meta-analysis of randomized controlled trials. Medicine. 2016;95:e3600.","journal-title":"Medicine"},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","volume":"123","author":"B Pasternak","year":"2011","unstructured":"Pasternak B, Svanstr\u00f6m H, Callr\u00e9us T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729\u201336.","journal-title":"Circulation"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/01.RES.0000088358.99466.04","volume":"93","author":"R Benndorf","year":"2003","unstructured":"Benndorf R, B\u00f6ger RH, Erg\u00fcn S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res. 2003;93:438\u201347.","journal-title":"Circ Res"},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1096\/fj.03-0129com","volume":"17","author":"T Walther","year":"2003","unstructured":"Walther T, Menrad A, Orzechowski H-D, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17:2061\u20137.","journal-title":"FASEB J"},{"key":"1021_CR24","unstructured":"U.S. Government Accountability Office. Drug pricing: research on savings from generic drug use. 2012 [cited 2019 Dec 18]; Available from: https:\/\/www.gao.gov\/products\/GAO-12-371R"},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/978-3-319-20206-8_17","volume-title":"Excipient applications in formulation design and drug delivery","author":"B Munjal","year":"2015","unstructured":"Munjal B, Koradia V, Boddu SHS, Bansal AK. Role of innovator product characterization in generic product development. In: Narang AS, Boddu SHS, editors. Excipient applications in formulation design and drug delivery. Cham: Springer International Publishing; 2015. p. 521\u201338."},{"key":"1021_CR26","unstructured":"Center for Drug Evaluation and Research. Laboratory analysis of valsartan products. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/laboratory-analysis-valsartan-products."},{"key":"1021_CR27","unstructured":"Francisco EM. Sartan medicines: companies to review manufacturing processes avoid presence of nitrosamine impurities - European Medicines Agency. European Medicines Agency. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities."},{"key":"1021_CR28","unstructured":"Office of the Commissioner. What we do. U.S. Food and Drug Administration. 2018 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/about-fda\/what-we-do."},{"key":"1021_CR29","unstructured":"Office of the Commissioner. What does FDA regulate?. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/about-fda\/fda-basics\/what-does-fda-regulate."},{"key":"1021_CR30","unstructured":"Center for Drug Evaluation and Research. Drug recalls. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/drug-recalls."},{"key":"1021_CR31","unstructured":"Center for Drug Evaluation and Research. FDA\u2019s role in drug recalls. U.S. Food and Drug Administration. 2018 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-recalls\/fdas-role-drug-recalls."},{"key":"1021_CR32","unstructured":"United States Government Accountability Office. Drug safety: FDA has improved its Foreign Drug Inspection Program, but needs to assess the effectiveness and staffing of its foreign offices. 2016."},{"key":"1021_CR33","unstructured":"Committee on Energy and Commerce Staff. Memorandum: Hearing on \u201cSecuring the U.S. Drug Supply Chain: Oversight of FDA\u2019s Foreign Inspection Program.\u201d 2019."},{"key":"1021_CR34","unstructured":"Van Arnum P. API Sourcing: The supply side for US-marketed drugs. Value Chain INSIGHTS. 2019 [cited 2019 Dec 19]. Available from: https:\/\/dcatvci.org\/6213-global-api-sourcing-which-countries-lead."},{"key":"1021_CR35","unstructured":"Center for Drug Evaluation and Research. Facts about the current good manufacturing practices (CGMPs). U.S. Food and Drug Administration. [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/facts-about-current-good-manufacturing-practices-cgmps."},{"key":"1021_CR36","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry ANDAs: Impurities in Drug Substances. FDA; 1999."},{"key":"1021_CR37","unstructured":"Edney A, Berfield S, Yu E. Carcinogens have infiltrated the generic drug supply in the U.S. Bloomberg News. Bloomberg; 2019 [cited 2019 Dec 18]; Available from: https:\/\/www.bloomberg.com\/news\/features\/2019-09-12\/how-carcinogen-tainted-generic-drug-valsartan-got-past-the-fda."},{"key":"1021_CR38","unstructured":"Center for Drug Evaluation and Research. Sciegen Pharmaceuticals, Inc. Issues voluntary nationwide recall of irbesartan tablets, USP 75 mg, 150 mg, and 300 mg due to the detection of trace amounts of NDEA (N-Nitrosodiethylamine) impurity found in the active pharmaceutical ingredient (API). U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/sciegen-pharmaceuticals-inc-issues-voluntary-nationwide-recall-irbesartan-tablets-usp-75-mg-150-mg."},{"key":"1021_CR39","unstructured":"Health Canada. Impurities found in certain angiotensin II receptor blocker (ARB) products, also known as sartans - Canada.ca. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/angiotensin-receptor-blocker.html."},{"key":"1021_CR40","unstructured":"Center for Drug Evaluation and Research. Search list of recalled ARBs: valsartan, losartan and irbesartan. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and."},{"key":"1021_CR41","unstructured":"Office of the Commissioner. FDA Statement on the FDA\u2019s ongoing investigation into valsartan and ARB class impurities and the agency\u2019s steps to address the root causes of the safety issues. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps."},{"key":"1021_CR42","unstructured":"Center for Drug Evaluation and Research. Lantech Pharmaceuticals Limited - 580027 - 08\/08\/2019. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 21]. Available from: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/lantech-pharmaceuticals-limited-580027-08082019."},{"key":"1021_CR43","unstructured":"Avoxa \u2013 Mediengruppe Deutscher Apotheker GmbH. Valsartan: ZL findet NDMA in tabletten. Pharmazeutische Zeitung online. Avoxa \u2013 Mediengruppe Deutscher Apotheker GmbH; [cited 2019 Dec 18]. Available from: https:\/\/www.pharmazeutische-zeitung.de\/ausgabe-302018\/zl-findet-ndma-in-tabletten\/."},{"key":"1021_CR44","unstructured":"Burton TM. FDA says up to two million people exposed to likely carcinogens in blood-pressure drugs. WSJ Online. wsj.com; 2019 [cited 2019 Dec 18]; Available from: https:\/\/www.wsj.com\/articles\/fda-says-up-to-two-million-people-exposed-to-likely-carcinogens-in-blood-pressure-drugs-11548427981."},{"key":"1021_CR45","unstructured":"Center for Drug Evaluation and Research. Transcript: Angiotensin II receptor blockers (ARBs). U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/transcript-angiotensin-ii-receptor-blockers-arbs-message-patients."},{"key":"1021_CR46","unstructured":"Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. European Medicines Agency. 2018 [cited 2019 Dec 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group."},{"key":"1021_CR47","unstructured":"Center for Drug Evaluation and Research. FDA\u2019s assessment of currently marketed ARB drug products [Internet]. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fdas-assessment-currently-marketed-arb-drug-products."},{"key":"1021_CR48","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.13955","volume":"74","author":"PM Gunasekaran","year":"2019","unstructured":"\u2022 Gunasekaran PM, Chertow GM, Bhalla V, Byrd JB. Current status of angiotensin receptor blocker recalls. Hypertension. 2019;74:1275\u20138 A recently published update on the current status of the ARB recalls, with attention to some questions still requiring answers.","journal-title":"Hypertension"},{"key":"1021_CR49","unstructured":"Office of the Commissioner. FDA Statement on the agency\u2019s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency\u2019s ongoing efforts to resolve ongoing safety issue. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-agencys-list-known-nitrosamine-free-valsartan-and-arb-class-medicines-part-agencys."},{"key":"1021_CR50","unstructured":"Center for Drug Evaluation and Research. FDA updates & press on ARB recalls: valsartan, losartan and irbesartan. 2019. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan."},{"key":"1021_CR51","unstructured":"World Health Organization. N-Nitrosodimethylamine in drinking-water. 2003. Available from: https:\/\/www.who.int\/water_sanitation_health\/dwq\/chemicals\/ndma2ndadd.pdf."},{"key":"1021_CR52","unstructured":"FastStats. Centers for Disease Control and Prevention. 2019 [cited 2019 Dec 18]. Available from: https:\/\/www.cdc.gov\/nchs\/fastats\/body-measurements.htm."},{"key":"1021_CR53","unstructured":"World Health Organization. Concise International Chemical Assessment Document 38: N-NITROSODIMETHYLAMINE. 2002."},{"key":"1021_CR54","unstructured":"Office of the Commissioner. Statement from Janet Woodcock, M.D., director of FDA\u2019s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U. S. U.S. Food and Drug Administration. 2019 [cited 2019 Dec 21]. Available from: http:\/\/www.fda.gov\/news-events\/press-announcements\/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found."},{"key":"1021_CR55","unstructured":"Recalls of angiotensin II receptor blockers (ARBs) including valsartan, losartan and irbesartan. U.S. Food and Drug Administration. 2019 [cited 2020 Jan 10]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/recalls-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and-irbesartan."}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-1021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-020-1021-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-1021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:53:08Z","timestamp":1614473588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-020-1021-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s11906-020-1021-0","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,29]]},"assertion":[{"value":"29 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"20"}}